Segment Information

6 Months Ended

Mar. 31, 2023

Segment Reporting [Abstract]

Segment Information

13. Segment Information

Segment revenue, operating loss, and depreciation and amortization were as follows:

	Three Months Ended March 31,						Six Months Ended March 31,
(In thousands)	2023			2022			2023			2022
Revenue:
Medical Device	$	19,707		$	18,453		$	38,725		$	35,361
In Vitro Diagnostics		7,491			7,653			13,406			13,748
Total revenue	$	27,198		$	26,106		$	52,131		$	49,109
Operating (loss) income:
Medical Device	$	(7,059	)	$	(5,612	)	$	(14,294	)	$	(9,404	)
In Vitro Diagnostics		3,636			3,720			6,584			6,875
Total segment operating (loss) income		(3,423	)		(1,892	)		(7,710	)		(2,529	)
Corporate		(3,160	)		(3,008	)		(6,102	)		(5,812	)
Total operating (loss) income	$	(6,583	)	$	(4,900	)	$	(13,812	)	$	(8,341	)
Depreciation and amortization:
Medical Device	$	1,933		$	2,133		$	3,886		$	4,327
In Vitro Diagnostics		75			86			152			172
Corporate		84			101			176			197
Total depreciation and amortization	$	2,092		$	2,320		$	4,214		$	4,696

The Corporate category includes expenses that are not fully allocated to the Medical Device and In Vitro Diagnostics segments. These Corporate costs are related to administrative corporate functions, such as executive management, corporate accounting, information technology, legal, human resources and Board of Directors. Corporate may also include expenses, such as acquisition-related costs and litigation, which are not specific to a segment and thus not allocated to the reportable segments.

Asset information by segment is not presented because the Company does not provide its chief operating decision maker assets by segment, as the data is not readily available.